Syndax Pharmaceuticals, Inc. Selling, General and Administrative Expense
Syndax Pharmaceuticals, Inc. (SNDX) reported Selling, General and Administrative Expense of $179.68 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-02-26
- Syndax Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2025 was $179.68M, a 48.65% increase from fiscal 2024.
- Syndax Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2024 was $120.88M, a 80.63% increase from fiscal 2023.
- Syndax Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2023 was $66.92M, a 101.22% increase from fiscal 2022.
- Syndax Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2022 was $33.26M, a 31.76% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 12 month |
|---|---|
| 2025-12-31 | $179.68M 10-K · filed 2026-02-26 |
| 2024-12-31 | $120.88M 10-K · filed 2026-02-26 |
| 2023-12-31 | $66.92M 10-K · filed 2026-02-26 |
| 2022-12-31 | $33.26M 10-K · filed 2025-03-03 |
| 2021-12-31 | $25.24M 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |